APOLLOHOSP:NSE-Apollo Hospitals Enterprise Limited (INR)

COMMON STOCK | Medical Care Facilities | NSE

Last Closing Price

INR 1,817.80

Change

+28.65 (+1.60)%

Market Cap

INR 252.90B

Volume

1.42M

Average Target Price

INR 1,970.00 (+8.37%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India and internationally. The company's healthcare facilities comprise primary, secondary, and tertiary care facilities. Its tertiary care hospitals provide care in approximately 55 specialties, including cardiac sciences, oncology, critical care, neurosciences, orthopedics, gastroenterology, and transplants. The company also provides other services, such as project consultancy, health insurance, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. The company's footprint includes 10,167 beds, 3,428 pharmacies, and 765 retail healthcare centers. Apollo Hospitals Enterprise Limited was founded in 1979 and is based in Chennai, India. Address: Sunny Side Building, Chennai, India, 600006

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-23 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
FORTIS:NSE Fortis Healthcare Limited

+2.85 (+2.16%)

INR101.92B 25.86 26.04
ASTERDM:NSE Aster DM Healthcare Limited

+0.05 (+0.04%)

INR68.08B 36.25 10.65
NH:NSE Narayana Hrudayalaya Limited

+0.60 (+0.18%)

INR66.88B 39.73 32.54
MAXINDIA:NSE Max Healthcare Institute Limit..

N/A

INR18.42B 5.20 N/A
HCG:NSE HealthCare Global Enterprises ..

-0.65 (-0.54%)

INR14.99B N/A 21.60
SHALBY:NSE Shalby Limited

-0.15 (-0.20%)

INR7.91B 24.37 9.69
INDRAMEDCO:NSE Indraprastha Medical Corporati..

+0.35 (+0.75%)

INR4.27B 47.08 13.41
LOTUSEYE:NSE Lotus Eye Hospital and Institu..

-0.05 (-0.17%)

INR0.58B 30.45 10.66

ETFs Containing APOLLOHOSP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.44% 89% B+ 78% C+
Dividend Return 0.19% 50% F 14% F
Total Return 27.64% 89% B+ 78% C+
Trailing 12 Months  
Capital Gain 25.10% 78% C+ 79% C+
Dividend Return 0.19% 50% F 12% F
Total Return 25.29% 78% C+ 79% C+
Trailing 5 Years  
Capital Gain 29.01% 75% C 66% D
Dividend Return 1.83% 33% F 18% F
Total Return 30.84% 75% C 65% D
Average Annual (5 Year Horizon)  
Capital Gain 3.15% N/A N/A N/A N/A
Dividend Return 0.42% N/A N/A N/A N/A
Total Return 3.56% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.34% N/A N/A N/A N/A
Risk Adjusted Return 19.43% N/A N/A N/A N/A
Market Capitalization 252.90B 100% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 130.48 13% F 6% F
Price/Book Ratio 7.40 11% F 8% F
Price / Cash Flow Ratio 19.56 22% F 18% F
EV/EBITDA 18.67 50% F 28% F
Management Effectiveness  
Return on Equity 12.44% 89% B+ 67% D+
Return on Invested Capital 13.79% 89% B+ 82% B-
Return on Assets 5.92% 89% B+ 73% C
Debt to Equity Ratio 85.41% 25% F 19% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.37 67% D+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector